Fontan-Sprechstunde

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-60
SponsorUniversity of Erlangen-Nürnberg Medical School

About this trial

After successful Fontan surgery, the risk of mortality in childhood is only low. Unfortunately, some of the patients suffer from Fontan-typical long-term complications in the long-term course, whereby protein loss neuropathy must be mentioned in particular, which is described in the literature with an incidence of 3-14% (1, 2) and still has a 5-year risk of death of 6-12% today (2, 3). Protein loss tereopathy leads to loss of protein in the intestine and subsequently to diarrhea and edema. Other problems concern the liver, which can develop cirrhosis due to chronic congestion (4-6). Cardiac can lead to heart failure and arrhythmias.

The registry study described in this protocol is intended to identify factors that influence the treatment outcome of patients in the Fontan circulation in the long term through systematic prospective documentation of the data from our standardized and guideline-oriented treatment.

Eligibility criteria

Qualifiers

congenital heart defect of the univentricular type that has led to Fontan circulation

Disqualifiers

no exclusion criteria

Trial design

Treatments tested in this trial

  • Univentricular Hearts

Treatment groups

200 Participants
are divided into 1 treatment group